Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target
Complete. Here is the key summaryLifeSci Capital analyst Francois Brisebois maintains a Buy rating on Larimar Therapeutics (LRMR) with an unchanged $25 price target. The decision is driven by nomlabofusp's progress toward FDA approval, including a rolling BLA submission for Friedreich’s ataxia, and durable clinical efficacy showing sustained FXN levels and functional benefits over 18 months. These factors support the potential for disease modification and attractive upside despite limited cash runway.
In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics, with a price target of $25.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Francois Brisebois has given his Buy rating due to a combination of factors, including the steady progress of nomlabofusp toward approval and the durability of its clinical effects. The company has initiated a rolling BLA submission for nomlabofusp in Friedreich’s ataxia, and long-term open-label data show sustained increases in FXN levels into the carrier range for most participants through 18 months, supporting a potential disease-modifying profile.
Clinically, patients on nomlabofusp demonstrated meaningful functional benefits, with improvements in mFARS scores versus expected decline from the FACOMS reference cohort, and the advantage appeared to grow by 18 months, even in a population with greater baseline disease severity. These efficacy and durability signals, combined with a clear regulatory path via accelerated approval and an unchanged $25 price target, underpin Brisebois’s conviction that LRMR shares offer attractive upside despite the company’s limited cash runway.
Francois Brisebois has given his Buy rating due to a combination of factors, including the steady progress of nomlabofusp toward approval and the durability of its clinical effects. The company has initiated a rolling BLA submission for nomlabofusp in Friedreich’s ataxia, and long-term open-label data show sustained increases in FXN levels into the carrier range for most participants through 18 months, supporting a potential disease-modifying profile.
Clinically, patients on nomlabofusp demonstrated meaningful functional benefits, with improvements in mFARS scores versus expected decline from the FACOMS reference cohort, and the advantage appeared to grow by 18 months, even in a population with greater baseline disease severity. These efficacy and durability signals, combined with a clear regulatory path via accelerated approval and an unchanged $25 price target, underpin Brisebois’s conviction that LRMR shares offer attractive upside despite the company’s limited cash runway.
In another report released on June 26, Citi also maintained a Buy rating on the stock with a $14.00 price target.